HeartSciences Inc. (HSCS)

Over the past six months, HeartSciences' stock has experienced volatility, with a 52-week trading range between $2.53 and $6.47. Key events impacting the stock include the release of financial results and business updates, participation in conferences and investor webinars, and the FDA Breakthrough Device Designation for its aortic stenosis AI-ECG algorithm. The company's revenue for fiscal year 2025 was $4,350, a decrease of 76.61% from the previous year, with losses of -$8.77 million. HeartSciences reported no meaningful revenue for the first quarter of fiscal 2026.

The provided information does not explicitly detail the demand seasonality for HeartSciences, Inc.'s products and services. The demand for medical devices and diagnostic solutions is generally driven by factors such as the rising prevalence of cardiovascular diseases. The company's focus on improving healthcare through earlier detection of heart disease suggests a continuous need for its solutions, independent of specific seasons.

HeartSciences, Inc. is a medical technology company that uses artificial intelligence to improve the clinical utility of electrocardiograms. The company's primary objective is to transform ECGs/EKGs to enable earlier detection of heart disease. Its major products and solutions include AI-ECG solutions, the MyoVista wavECG™ Device, and the MyoVista Insights™ cloud-platform.

HeartSciences is headquartered in Southlake, Texas, United States, and holds an extensive intellectual property portfolio with 44 granted patents worldwide. The MyoVista Device is not currently FDA cleared and is not available in the United States, but HeartSciences aims for its AI-ECG diagnostic solutions to be used in healthcare settings globally.

HeartSciences' brand reputation is primarily shaped by its technological advancements and regulatory progress in the medical technology space. Positive events contributing to its reputation include the FDA Breakthrough Device Designation, partnership with Mount Sinai, extensive IP portfolio and clinical validation, and the launch of MyoVista Insights. However, its financial performance, with declining revenue and ongoing losses, could be a point of concern for investors and potentially impact its broader reputation in the financial markets.

HeartSciences has a mix of institutional and individual ownership, with approximately 2.89% of the stock owned by institutional investors and 97.11% by retail investors. Insiders own about 3.5% of the company's shares. Major institutional owners include DRW Securities, LLC, TFB Advisors LLC, and Vanguard Group Inc. Key individual insiders with significant holdings include Andrew Simpson, Danielle Watson, and Bruce Bent.